NAD+, NMN, and NR: The Longevity Molecules Explained

NAD+ (nicotinamide adenine dinucleotide) is arguably the most important molecule in your body that you've never had tested. It's required for over 500 enzymatic reactions, it's the primary substrate for sirtuins (your longevity genes), and it declines roughly 50% between age 40 and 60. That decline correlates with — and likely causes — many hallmarks of aging.

The question isn't whether NAD+ matters. The question is whether supplementing its precursors (NMN and NR) actually raises tissue levels enough to matter. The answer is more nuanced than the supplement industry wants you to believe.

What NAD+ Actually Does

NAD+ is a coenzyme present in every living cell. It exists in two forms: NAD+ (oxidized) and NADH (reduced). Together they shuttle electrons in metabolic reactions.

Critical functions:

• Energy metabolism — NAD+ is essential for glycolysis, the TCA cycle, and oxidative phosphorylation. Without it, your mitochondria can't produce ATP.
• Sirtuin activation — Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that regulate DNA repair, inflammation, metabolism, and circadian rhythm. No NAD+, no sirtuin activity.
• DNA repair — PARP enzymes (PARP1, PARP2) consume NAD+ to repair DNA damage. This is actually a major NAD+ sink — chronic DNA damage can deplete your pool.
• Epigenetic regulation — NAD+ influences histone modifications and gene expression patterns.
• Immune function — CD38, an NAD+-consuming enzyme on immune cells, increases with age and is now considered a primary driver of age-related NAD+ decline.

Why NAD+ Declines With Age

This is where it gets interesting. NAD+ doesn't just passively decrease — it's actively consumed by processes that accelerate with age:

CD38 upregulation — CD38 expression on immune cells and senescent cells increases dramatically with age and chronic inflammation. CD38 is an NAD+ glycohydrolase — it literally destroys NAD+. Some researchers now believe CD38 is the primary cause of age-related NAD+ decline, not reduced synthesis.

Increased PARP activity — More DNA damage (from oxidative stress, UV exposure, metabolic dysfunction) means more PARP activation, which consumes more NAD+.

Reduced NAMPT — NAMPT is the rate-limiting enzyme in NAD+ salvage synthesis. Its expression decreases with age, slowing your ability to recycle NAD+.

Chronic inflammation — Inflammation drives both CD38 expression and DNA damage, creating a vicious cycle of NAD+ depletion.

NMN vs NR: The Precursor Debate

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors. They enter the salvage pathway at slightly different points.

NMN:

• One enzymatic step from NAD+ (NMN → NAD+ via NMNAT)


• Molecular weight: 334 g/mol


• Must be converted to NR to cross cell membranes (via the Slc12a8 transporter, which is tissue-specific) — or it enters directly in tissues that express Slc12a8


• Most clinical data uses 250-1000mg/day


• More expensive per dose

NR:

• Two enzymatic steps from NAD+ (NR → NMN → NAD+)


• Molecular weight: 255 g/mol


• Readily crosses cell membranes via nucleoside transporters


• Most clinical data uses 300-1000mg/day


• Better-established patent portfolio (ChromaDex/Niagen)

The honest answer: In clinical trials, both raise blood NAD+ levels. NR has more published human data (Niagen has been in clinical trials longer). NMN has stronger animal data and more recent human trials. Neither has demonstrated a definitive clinical advantage over the other in humans.

What the Human Data Actually Shows

NMN human trials:

• Yoshino et al. (2021, Science): 250mg/day for 10 weeks in overweight/obese postmenopausal women improved insulin sensitivity in skeletal muscle. No effect on body composition, blood pressure, or lipids.
• Yi et al. (2022): 1000mg/day for 6 weeks improved sleep quality, reduced fatigue, and improved physical performance in middle-aged adults.
• Igarashi et al. (2022): 250mg/day for 12 weeks improved grip strength and gait speed in elderly men.

NR human trials:

• Martens et al. (2018): 1000mg/day for 6 weeks raised NAD+ levels by ~60% in healthy middle-aged adults. Trends toward reduced blood pressure and arterial stiffness (not statistically significant).
• Dollerup et al. (2018): 2000mg/day for 12 weeks in obese men with insulin resistance. No improvement in insulin sensitivity, body composition, or energy expenditure.
• Elhassan et al. (2019): 1000mg/day for 21 days in elderly men raised skeletal muscle NAD+ by ~2.3x and reduced inflammatory cytokines.

The pattern: Both precursors reliably raise blood and tissue NAD+ levels. The downstream clinical benefits are modest, inconsistent, and mostly in older or metabolically compromised populations. Neither has shown dramatic anti-aging effects in humans — yet.

Dosing Protocol

Based on available evidence:

NMN: 500-1000mg/day, taken in the morning (NAD+ is circadian-regulated — higher in the morning supports natural rhythm). Sublingual delivery may improve bioavailability by bypassing first-pass metabolism.

NR: 300-1000mg/day, taken in the morning. Niagen (by ChromaDex) is the most-studied form.

With food or without: Data is mixed. Some protocols use fasting state (theoretical better absorption), others with a small meal. Not a critical variable.

Cycling: Some practitioners recommend cycling (5 days on, 2 off) to prevent downregulation of salvage pathway enzymes. This is theoretical — no clinical data supports or refutes it.

The CD38 Problem (and Why It Matters)

Here's something most NAD+ supplement companies don't mention: if CD38 is destroying your NAD+ faster than you can produce it, supplementing precursors is like trying to fill a bathtub with the drain open.

CD38 inhibitors are potentially more important than NAD+ precursors:

• Apigenin (found in chamomile, parsley) — CD38 inhibitor in vitro, poor oral bioavailability
• Quercetin — mild CD38 inhibition
• Luteolin — stronger CD38 inhibitor than apigenin in some assays
• 78c — potent synthetic CD38 inhibitor (research tool, not available as supplement)

A combined strategy — NAD+ precursor + CD38 inhibitor + lifestyle factors that reduce chronic inflammation — is likely more effective than any single supplement.

Cost-Benefit Analysis

Quality NMN: ~$1-2/day at 500mg
Quality NR (Niagen): ~$1.50-2.50/day at 300mg

Who benefits most:

• Adults over 45 (when NAD+ decline becomes clinically relevant)


• People with metabolic dysfunction (insulin resistance, obesity)


• Anyone with chronic inflammation or high oxidative stress


• Potentially: athletes with high training volume (PARP activation from exercise-induced DNA damage)

Who probably doesn't need it:

• Healthy adults under 35 with good metabolic markers


• Anyone who'd benefit more from fixing sleep, diet, or exercise first

The Bottom Line

NAD+ precursors are one of the more promising longevity interventions, but the human data is still early. They reliably raise NAD+ levels. Whether that translates to meaningful lifespan or healthspan extension in humans remains unproven.

If you're over 40, metabolically healthy, and have your foundational habits dialed, NMN or NR is a reasonable addition at 500-1000mg/day. If you're under 40 with suboptimal sleep, nutrition, or training — fix those first. The ROI on sleep is 100x the ROI on any NAD+ precursor.

Don't buy into the hype that NAD+ supplementation is a substitute for the fundamentals. It's a potential accelerant on top of an already-optimized foundation.